IP Verse

A Method For Treating Melanoma Using A Herpes Simplex Virus And An Immune Checkpoint Inhibitor - EP3381942

The patent EP3381942 was granted to Amgen on Oct 1, 2025. The application was originally filed on Aug 30, 2013 under application number EP18157842A. The patent is currently recorded with a legal status of "Patent Maintained As Amended".

EP3381942

AMGEN
Application Number
EP18157842A
Filing Date
Aug 30, 2013
Status
Patent Maintained As Amended
Aug 29, 2025
Grant Date
Oct 1, 2025
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

HOFFMANN EITLEJan 13, 2022-WITHDRAWN

Patent Citations (25) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONUS5811097
DESCRIPTIONUS5855887
DESCRIPTIONUS6051227
DESCRIPTIONUS6207157
DESCRIPTIONUS6682736
DESCRIPTIONUS6984720
DESCRIPTIONUS7223593
DESCRIPTIONUS7488802
DESCRIPTIONUS7537924
DESCRIPTIONUS7605238
DESCRIPTIONUS7943743
DESCRIPTIONUS8008449
DESCRIPTIONUS8168757
DESCRIPTIONUS8217149
DESCRIPTIONWO03042402
DESCRIPTIONWO2008156712
DESCRIPTIONWO2010036959
DESCRIPTIONWO2010089411
DESCRIPTIONWO2011066342
DESCRIPTIONWO2011082400
DESCRIPTIONWO2011159877
DESCRIPTIONWO2011161699
OPPOSITIONEP137602215
OPPOSITIONWO2014036412
SEARCHWO0153506

Non-Patent Literature (NPL) Citations (85) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- BATCH et al., J Clin Oncol., (20090000), vol. 27, no. 36, pages 6199 - 6206-
DESCRIPTION- BLOIS et al., Cancer, (19830000), vol. 52, no. 7, pages 1330 - 1341-
DESCRIPTION- BRIGNONE et al., J. Immunol., (20070000), vol. 179, pages 4202 - 4211-
DESCRIPTION- CLARK et al., J. National Cancer Inst., (19890000), vol. 81, no. 24, pages 1893 - 1904-
DESCRIPTION- FONG et al., Cancer Res., (20090000), vol. 69, no. 2, pages 609 - 615-
DESCRIPTION- FOURCADE et al., J. Exp. Med., (20100000), vol. 207, pages 2175 - 86-
DESCRIPTION- HARRINGTON et al., J Clin Oncol., (20090000), vol. 27, no. 15a-
DESCRIPTION- HODI et al., N Eng J Med., (20100000), vol. 363, pages 711 - 723-
DESCRIPTION- HU et al., Clin Can Res, (20060000), vol. 12, pages 6737 - 6747-
DESCRIPTION- HUNTER et al., J Virol, (19990000), vol. 73, no. 8, pages 6319 - 6326-
DESCRIPTION- JEMAL et al., CA Cancer J Clin., (20060000), vol. 56, pages 106 - 130-
DESCRIPTION- KAPADIA; FONG, J Clin Oncol., (20050000), vol. 23, pages 8926 - 8928-
DESCRIPTION- KARAKOUSIS et al., Ann Surg Oncol, (20060000), vol. 13, pages 533 - 541-
DESCRIPTION- KAUFMAN; BINES, Future Oncol., (20100000), vol. 6, no. 6, pages 941 - 949-
DESCRIPTION- KAUFMAN et al., Ann Surgic Oncol., (20100000), vol. 17, pages 718 - 730-
DESCRIPTION- KAUFMAN et al., Ann Surg Oncol., (20100000), vol. 17, no. 3, pages 718 - 730-
DESCRIPTION- KOH, NEJM, (19910000), vol. 325, no. 3, pages 171 - 182-
DESCRIPTION- LEON et al., Archives of Surgery, (19910000), vol. 126, no. 2, pages 1461 - 1468-
DESCRIPTION- LIU et al., Gene Ther, (20030000), vol. 10, pages 292 - 303-
DESCRIPTION- LOO et al., Clin. Cancer Res., (20120700), vol. 15, no. 18, page 3834-
DESCRIPTION- LUI et al., Gene Therapy, (20030000), vol. 10, pages 292 - 303-
DESCRIPTION- MACKIE et al., Lancet, (20010000), vol. 357, pages 525 - 526-
DESCRIPTION- MARKERT et al., Gene Ther, (20000000), vol. 7, pages 867 - 874-
DESCRIPTION- OVERETT; SHIU, Cancer, (19850000), vol. 56, pages 1222 - 1230-
DESCRIPTION- PARDOLL, Nature Reviews Cancer, (20120000), vol. 12, pages 252 - 264-
DESCRIPTION- RAMPLING et al., Gene Ther, (20000000), vol. 7, pages 859 - 866-
DESCRIPTION- RIES et al., Cancer, (20000000), vol. 88, pages 2398 - 2424-
DESCRIPTION- ROBERT et al., N Eng J Med., (20110000), vol. 364, pages 2517 - 2526-
DESCRIPTION- SAKUISHI et al., J. Exp. Med., (20100000), vol. 207, pages 2187 - 94-
DESCRIPTION- SCENZER et al., J. Clin. Oncol., (20090000), vol. 271, no. 12, pages 907 - 913-
DESCRIPTION- SENZER et al., J Clin Oncol., (20090000), vol. 27, no. 34, pages 5763 - 5771-
DESCRIPTION- SHUMATE et al., Am J Surgery, (19910000), vol. 162, no. 4, pages 315 - 319-
DESCRIPTION- SIEGEL et al., CA Cancer J Clin., vol. 62, no. 1, pages 10 - 29-
DESCRIPTION- SLINGUFF et al., Cancer, (19920000), vol. 70, no. 7, pages 1917 - 1927-
DESCRIPTION- SUNDARESAN et al., J. Virol, (20000000), vol. 74, pages 3822 - 3841-
DESCRIPTION- WEBER, Cancer Immunol. Immunother, (20090000), vol. 58, pages 823 - 830-
DESCRIPTION- WOLCHOK et al., Clin Cancer Res, (20090000), vol. 15, no. 23, pages 7412 - 7420-
OPPOSITION- ALEXANDER, Pharmacy & Therapeutics, (20120900), vol. 37, no. 9, pages 526 - 529, XP055196908-
OPPOSITION- Alexander, Pharmacy & Therapeutics, Sep 2012, 37(9):526-529-
OPPOSITION- Andtbacka et al. 2015 (J. Clin. Oncol., Vol. 33:2780-2788)-
OPPOSITION- Anonymous, "FDA Approves YERVOY (ipilimumab) for the Treatment of Patients with Newly Diagnosed or Previously- Treated Unresectable or Metastatic Melanoma, the Deadliest Form of Skin Cancer", Bristol Myers Squibb press release, (20110325), pages 1 - 5, XP055886412-
OPPOSITION- Boards of Appeal’s Preliminary opinion on European Patent Application No. 13760221.5 (T 709/18), 17 Feb 2021-
OPPOSITION- Bristol Myers Squibb press release - FDA Approves Yervoy, Mar 2011-
OPPOSITION- BusinessWire press release re: termination of activities for GVAX-
OPPOSITION- Chesney et al. 2017 (Abstract presented at the 2017 ASCO Annual Meeting)-
OPPOSITION- Chesney et al. 2017 (J. Clin. Oncol. 35: DOI: 10.1200/JCO.2017.73.7379 )-
OPPOSITION- Contents of Anticancer Research vol. 32, number 7 (July 2012)-
OPPOSITION- Declaration by Dr. Jennifer Gansert-
OPPOSITION- Declaration of Prof. Dr. Schadendorf-
OPPOSITION- Examining Division’s Decision to refuse European Patent Application No.13760221.5.-
OPPOSITION- Excerpt from clinicaltrials.gov-
OPPOSITION- FierceBiotech press release re: termination of activities for GVAX-
OPPOSITION- Gao et al., Cancer Gene Therapy, 2009; 16:44-52-
OPPOSITION- H. A. Franks, Et Al., "New Anticancer Immunotherapies", Anticancer Research, (20120101), vol. 32, pages 2439 - 2454, XP055392336-
OPPOSITION- Hodi et al. 2014 (JAMA, Vol. 312(17):1744-1753)-
OPPOSITION- Hurwitz et al., Proc. Natl. Acad. Sci. USA, Aug 1998, 95:10067-10071-
OPPOSITION- Jeffrey Weber, 2011 (Curr. Opin. in Oncol., Vol. 23(2):163-169)-
OPPOSITION- Kurozumi et al. 2007 (J. Natl. Cancer Inst., Vol. 99:1768-81)-
OPPOSITION- Li et al., Clin Cancer Res, Mar 2009; 15(5): 1623-1634-
OPPOSITION- Ribas et al. 2017 (Cell, Vol. 170:1109-1119)-
OPPOSITION- T 0667/08-
OPPOSITION- T 1212/97-
OPPOSITION- Timmons et al. 2016 (JOVE, Vol. 111, e45039)-
OPPOSITION- Topalian et al N Engl J Med, Jun 2012; 366(26):2443-2454-
OPPOSITION- van Elsas. Journal of Experimental Medicine, RockerfellerUniversity Press, US, vol. 190 (3): 355-366, 1999-
OPPOSITION- Wang et al. 2001 (Scand. J. Immunol., Vol. 54:453-458)-
OPPOSITION- WHO Drug Information, Vol. 24, No. 4, 2010-
OPPOSITION- GAO Y, ET AL, "Recombinant vesicular stomatitis virus targeted to Her2/neu combined with anti-CTLA4 antibody eliminates implanted mammary tumors", Cancer Gene Therapy, New York, (20090101), vol. 16, no. 1, doi:10.1038/CGT.2008.55, ISSN 0929-1903, pages 44 - 52, XP002606262
OPPOSITION- LIU B L ET AL, "ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties.", Gene Therapy, GB , (20030201), vol. 10, no. 4, doi:10.1038/sj.gt.3301885, ISSN 0969-7128, pages 292 - 303, XP002313120
OPPOSITION- F. Stephen Hodi et al, "Improved Survival with Ipilimumab in Patients with Metastatic Melanoma", New England Journal of Medicine, (20100819), vol. 363, no. 8, doi:10.1056/NEJMoa1003466, ISSN 00284793, pages 711 - 723, XP055015428
OPPOSITION- TOPALIAN SUZANNE L ET AL, "Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.", New England Journal of Medicine,, US , (20120628), vol. 366, no. 26, doi:10.1056/NEJMoa1200690, ISSN 1533-4406, pages 2443 - 2454, XP002767416
OPPOSITION- HURWITZ A. A., ET AL., "CTLA-4 BLOCKADE SYNERGIZES WITH TUMOR-DERIVED GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR FOR TREATMENT OF AN EXPERIMENTAL MAMMARY CARCINOMA.", Proceedings of the National Academy of Sciences, (19980101), vol. 95., no. 17., doi:10.1073/pnas.95.17.10067, ISSN 0027-8424, pages 10067 - 10071., XP000882999
OPPOSITION- VAN ELSAS, Journal of Experimental Medicine, (19990000), vol. 190, no. 3, pages 355 - 366, XP002966969
OPPOSITION- B. Li, M. Vanroey, C. Wang, T.-H. T. Chen, A. Korman, K. Jooss, "Anti-Programmed Death-1 Synergizes with Granulocyte Macrophage Colony-Stimulating Factor-Secreting Tumor Cell Immunotherapy Providing Therapeutic Benefit to Mice with Established Tumors", Clinical Cancer Research, (20090301), vol. 15, no. 5, doi:10.1158/1078-0432.CCR-08-1825, ISSN 10780432, pages 1623 - 1634, XP055166457
OPPOSITION- N. N. Senzer et al, "Phase II Clinical Trial of a Granulocyte-Macrophage Colony-Stimulating Factor-Encoding, Second-Generation Oncolytic Herpesvirus in Patients With Unresectable Metastatic Melanoma", Journal of Clinical Oncology, (20091201), vol. 27, no. 34, doi:10.1200/JCO.2009.24.3675, ISSN 0732183X, pages 5763 - 5771, XP055207592
OPPOSITION- Natarajan Nagendra, Telang Sucheta, Miller Donald, Chesney Jason, "Novel Immunotherapeutic Agents and Small Molecule Antagonists of Signalling Kinases for the Treatment of Metastatic Melanoma :", Drugs, NZ , (20110701), vol. 71, no. 10, doi:10.2165/11591380-000000000-00000, ISSN 0012-6667, pages 1233 - 1250, XP055797344
OTHER- FRANKS H. A. et al, "New Anticancer Immunotherapies", Anticancer Research, (20120700), vol. 32, pages 2439 - 2454, XP055392336-
OTHER- NATARAJAN N. et al, "Novel Immunotherapeutic Agents and Small Molecule Antagonists of Signalling Kinases for the Treatment of Metastatic Melanoma", Drugs, (20110700), vol. 71, no. 10, pages 1233 - 1250, XP055797344
SEARCH- HOWARD L KAUFMAN ET AL, "Local and Distant Immunity Induced by Intralesional Vaccination with an Oncolytic Herpes Virus Encoding GM-CSF in Patients with Stage IIIc and IV Melanoma", ANNALS OF SURGICAL ONCOLOGY, SPRINGER-VERLAG, NE, (20091114), vol. 17, no. 3, ISSN 1534-4681, pages 718 - 730, XP019765817 [Y] 1-12 * abstract *-
SEARCH- SHANTHI SIVENDRAN ET AL, "Melanoma Immunotherapy", MOUNT SINAI JOURNAL OF MEDICINE: A JOURNAL OF TRANSLATIONAL AND PERSONALIZED MEDICINE, (20101123), vol. 77, no. 6, doi:10.1002/msj.20215, ISSN 0027-2507, pages 620 - 642, XP055113024 [A] 1-12 * page 624, column r, paragraphs 2-3 * * page 625, column l, paragraph 2 - page 631, column l, paragraph 1 * * page 636, column r, paragraph 4 - page 637, column l, paragraph 1 *
SEARCH- LIU B L ET AL, "ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties", GENE THERAPY, NATURE PUBLISHING GROUP, GB, (20030201), vol. 10, no. 4, doi:10.1038/SJ.GT.3301885, ISSN 0969-7128, pages 292 - 303, XP002313120 [Y] 1-12 * abstract * * figures 2,3,6 * * page 293, column r, paragraph 3 - page 296, column l, paragraph 2 * * page 296, column r, paragraph 5 - page 299, column l, paragraph 1 * * page 300, column r, paragraph 2 - page 301, column l, paragraph 2 *
SEARCH- F. STEPHEN HODI ET AL, "Improved Survival with Ipilimumab in Patients with Metastatic Melanoma", NEW ENGLAND JOURNAL OF MEDICINE, (20100819), vol. 363, no. 8, doi:10.1056/NEJMoa1003466, ISSN 0028-4793, pages 711 - 723, XP055015428 [Y] 6 * abstract * * Discussion *
SEARCH- VAN ELSAS A ET AL, "Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTL-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors", THE JOURNAL OF EXPERIMENTAL MEDICINE, ROCKEFELLER UNIVERSITY PRESS, US, (19990802), vol. 190, no. 3, doi:10.1084/JEM.190.3.355, ISSN 0022-1007, pages 355 - 366, XP002966969 [Y] 1-7,11-12 * page 356, column l, paragraph 2 * * page 357, column l, paragraph 3 - page 359, column l, paragraph 1; figures 1,2 * * Discussion *
SEARCH- WEBER JEFFREY, "Immunotherapy for melanoma", CURRENT OPINION IN ONCOLOGY, (201103), vol. 23, no. 2, pages 163 - 169, XP009177499 [A] 1-12 * page 166, paragraphs 1,2,3 *
SEARCH- QUEZADA SERGIO A ET AL, "CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells", JOURNAL OF CLINICAL INVESTIGATION, AMERICAN SOCIETY FOR CLINICAL INVESTIGATION, US, (20060703), vol. 116, no. 7, doi:10.1172/JCI27745, ISSN 0021-9738, pages 1935 - 1945, XP002556462 [Y] 1-12 * abstract * * Introduction, Discussion *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents